The Food and Drug Administration, the FDA, has granted capmatinib a “breakthrough therapy” designation as a first-line treatment for Non-Small Cell Lung Cancer (NSCLC) patients with MET mutation, EGFR Wild-type and their disease is in advanced stages – stages IIIb, IV – were it is locally spread or has sent metastases to distant organs.
The capmatinib is taken orally and selectively binds to c-Met.
96.4% of patients had responded to capmatinib
The designation comes as a result of the positive results seen in the GEOMETRY mono-1 trial presented at the 2019 ASCO Annual Meeting. The results demonstrated that 96.4% of patients had responded to capmatinib!
On breakthrough designation –
An FDA breakthrough therapy designation acknowledges that the drug targets a serious or life-threatening disease and shows improvement over existing treatments, the standard protocols. The MET gene has been concluded to be a driver of NSCLC. The mutation in this gene occurs in about 3% to 4% of all cases of NSCLC and is associated with a poor prognosis.
The designation also allows for expedited development and regulatory review of the agent by the FDA.
Trial results –
Among the pretreated patients, the disease control rate, DCR, was close to 80%. The median duration of response, DOR, was close to 10 months and the median time was close to 5.5 months.
In the treatment-naïve cohort, the DCR was 96.4%! The median DOR was 11.14 months and the median PFS was 9.69 months.
Peripheral edema was the most common side event (7.5%) followed by fatigue (3.0%).
Conclusion –
The best treatment for a cancer patient is to get the most advanced cancer drugs in advanced stages of development. There, the hope and the chance to extend life go far beyond the standard protocols.
Contact us to find out what is the best treatment for YOU
TRIAL•IN Pharma
Do not give up on life!
Contact us 24/7 for free service matching:
Call center +44.2082.426.039
www.trial-in.com
